Topics
Glioblastoma | Treatment | Clinical trials | Navtemadlin
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Navtemadlin
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN,
Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA,
Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K,
Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S,
Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY,
Ligon KL, Beroukhim R.
Surgical window
of opportunity trial reveals mechanisms of response and resistance
to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
medRxiv
[Preprint]. 2024 Aug 14:2024.08.12.24311893. doi:
10.1101/2024.08.12.24311893. PMID:
39211865. Interventional study. ˍ
Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Azazmeh N,
Rashid R, Lin JR, Cusick M, Reynolds ARN, Fassinou ACR, Ayoub G,
Malinowski S, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS,
Spetz J, Desai A, Lieberman F, Palanichamy K, Fisher JD, Pelton K,
Huang RY, Sarosiek KA, Nabors LB, Holdhoff M, Danda N, Strowd R,
Desideri S, Walbert T, Ye X, Chakravarti A, Sorger PK, Santagata
S, Agar NYR, Grossman SA, Alexander BM, Wen PY, Ligon KL,
Beroukhim R.
A window-of-opportunity
trial reveals mechanisms of response and resistance to
navtemadlin in patients with
recurrent glioblastoma.
Sci
Transl Med. 2025 Feb 19;17(786):eadn6274. doi:
10.1126/scitranslmed.adn6274. PMID:
39970230. Interventional study˰
ˍ